Proactive Investors - Run By Investors For Investors

Forex headwinds could turn into tailwinds at Allergy Therapeutics

Allergy Therapeutics plc (LON:AGY) recently announced 19% growth on a constant currency basis in the year just ended, against a flat market backdrop.
To be delivering that sort of underlying growth in a becalmed market is a “good confirmation of the kind of things we’ve been hearing from Allergy on the commercial side for quite some time,” reckons Mike Mitchell, who covers the company at Allergy’s house broker Panmure Gordon.
Increasing market share by an average two percentage points during the reporting period bodes well for the future, Mitchell added.
For the year just gone, Mitchell notes, the company suffered forex headwinds thanks to the weakening euro, but “as the FX landscape moves forward” those headwinds could very well turn into tailwinds.
Britain’s impending exit from the European Union is likely to cause ripples in the sector, but as a company with a very strong commercial base and a pipeline of products that are in the mid-to-late stages of development, the Brexit risks are low in Mitchell’s view.

Meet Victoria Oil & Gas plc, Avation PLC and Greatland Gold plc at our event, London, 07 September 2017. Register here »
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use